Expansion	B:C0205229
of	O
the	O
Milan	O
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
the	O
pre-transplant	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
.	O

Expansion	O
of	O
the	O
Milan	B:C0679228
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
the	O
pre-transplant	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
.	O

Expansion	O
of	O
the	O
Milan	O
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
with	O
the	O
pre-transplant	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
.	O

Expansion	O
of	O
the	O
Milan	O
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
the	O
pre-transplant	B:C3841811
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
.	O

Expansion	O
of	O
the	O
Milan	O
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
the	O
pre-transplant	O
platelet	B:C0005821
-	O
to-	O
lymphocyte	O
ratio	O
.	O

Expansion	O
of	O
the	O
Milan	O
criteria	I:C0679228
without	O
any	O
sacrifice	O
:	O
combination	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
the	O
pre-transplant	O
platelet	O
-	O
to-	O
lymphocyte	B:C0024264
ratio	O
.	O

The	O
Hangzhou	B:C0679228
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	B:C0205229
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	B:C0679228
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	B:C0023911
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	B:C0023911
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	B:C3806166
outcomes	I:C3806166
due	O
to	O
early	O
tumor	O
recurrence	I:C0521158
.	O

The	O
Hangzhou	O
criteria	I:C0679228
expand	O
the	O
Milan	O
criteria	I:C0679228
safely	O
and	O
effectively	O
in	O
selecting	O
hepatocellular	O
carcinoma	I:C2239176
(	O
hepatocellular	O
carcinoma	I:C2239176
)	O
candidates	O
for	O
liver	O
transplantation	I:C0023911
(	O
liver	O
transplantation	I:C0023911
)	O
,	O
but	O
some	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
still	O
show	O
poor	O
outcomes	I:C3806166
due	O
to	O
early	O
tumor	B:C0521158
recurrence	I:C0521158
.	O

In	O
this	O
study	O
,	O
the	O
platelet	B:C0005821
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	B:C0024264
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	B:C0521158
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	B:C1709854
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	O
criteria	I:C0679228
was	O
established	O
.	O

In	O
this	O
study	O
,	O
the	O
platelet	O
-	O
to-	O
lymphocyte	O
ratio	O
(	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
)	O
was	O
employed	O
to	O
differentiate	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
,	O
and	O
a	O
new	O
method	O
combining	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
and	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
was	O
established	O
.	O

The	O
clinical	B:C1516606
data	I:C1516606
of	O
343	O
liver	O
transplantation	I:C0023911
for	O
hepatocellular	O
carcinoma	I:C2239176
were	O
retrospectively	O
analyzed	O
.	O

The	O
clinical	O
data	I:C1516606
of	O
343	O
liver	B:C0023911
transplantation	I:C0023911
for	O
hepatocellular	O
carcinoma	I:C2239176
were	O
retrospectively	O
analyzed	O
.	O

The	O
clinical	O
data	I:C1516606
of	O
343	O
liver	O
transplantation	I:C0023911
for	O
hepatocellular	B:C2239176
carcinoma	I:C2239176
were	O
retrospectively	O
analyzed	O
.	O

The	O
clinical	O
data	I:C1516606
of	O
343	O
liver	O
transplantation	I:C0023911
for	O
hepatocellular	O
carcinoma	I:C2239176
were	O
retrospectively	O
analyzed	B:C0936012
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	B:C0936012
was	O
used	O
to	O
determine	O
the	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
cut	O
-	O
off	O
value	O
to	O
stratify	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
cut	O
-	O
off	O
value	O
to	O
stratify	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
cut	O
-	O
off	O
value	O
to	O
stratify	O
patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
cut	O
-	O
off	O
value	O
to	O
stratify	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
.	O

The	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
(	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
)	O
of	O
recipients	O
was	O
compared	O
after	O
stratification	O
.	O

The	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
(	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
)	O
of	O
recipients	O
was	O
compared	O
after	O
stratification	O
.	O

The	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
(	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
)	O
of	O
recipients	B:C1709854
was	O
compared	O
after	O
stratification	O
.	O

The	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
(	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
)	O
of	O
recipients	O
was	O
compared	O
after	O
stratification	B:C1514983
.	O

The	O
Hangzhou	B:C0679228
criteria	I:C0679228
&	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
proposed	O
and	O
its	O
feasibility	O
was	O
validated	O
by	O
ROC	O
analysis	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
&	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
proposed	O
and	O
its	O
feasibility	O
was	O
validated	O
by	O
ROC	O
analysis	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
&	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
proposed	O
and	O
its	O
feasibility	O
was	O
validated	O
by	O
ROC	O
analysis	B:C0936012
.	O

platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
120	O
was	O
the	O
most	O
significant	O
cut	O
-	O
off	O
value	O
when	O
comparing	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
120	O
was	O
the	O
most	O
significant	O
cut	O
-	O
off	O
value	O
when	O
comparing	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
120	O
was	O
the	O
most	O
significant	O
cut	O
-	O
off	O
value	O
when	O
comparing	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
120	O
was	O
the	O
most	O
significant	O
cut	O
-	O
off	O
value	O
when	O
comparing	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
.	O

After	O
stratification	B:C1514983
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	O
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

After	O
stratification	O
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	O
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

After	O
stratification	O
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	O
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

After	O
stratification	O
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	O
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

After	O
stratification	O
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	O
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

After	O
stratification	O
,	O
the	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
<	O
120	O
were	O
84.2	O
%	O
,	O
73.3	O
%	O
,	O
and	O
73.3	O
%	O
,	O
respectively	O
,	O
comparable	O
with	O
85.7	O
%	O
,	O
73.9	O
%	O
,	O
and	O
72.8	O
%	O
,	O
respectively	O
,	O
in	O
patients	O
fulfilling	O
the	O
Milan	B:C0679228
criteria	I:C0679228
(	O
P	O
=	O
0.885	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	O
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	O
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	O
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	O
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	O
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	O
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	B:C3806166
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	O
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	O
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

Patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
with	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
showed	O
poor	O
outcomes	I:C3806166
,	O
which	O
were	O
similar	O
in	O
patients	O
exceeding	O
the	O
Hangzhou	O
criteria	I:C0679228
;	O
1-	O
,	O
3	O
-	O
,	O
and	O
5	O
-	O
year	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
were	O
only	O
37.5	O
%	O
,	O
12.5	O
%	O
,	O
and	O
12.5	O
%	O
vs.	O
32.3	O
%	O
,	O
17.6	O
%	O
,	O
and	O
15.1	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.887	O
)	O
.	O

ROC	O
analysis	B:C0936012
demonstrated	O
that	O
the	O
ROC	O
area	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
&	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
0.768	O
for	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
.	O

ROC	O
analysis	O
demonstrated	O
that	O
the	O
ROC	O
area	O
of	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
&	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
0.768	O
for	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
.	O

ROC	O
analysis	O
demonstrated	O
that	O
the	O
ROC	O
area	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
&	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
0.768	O
for	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
.	O

ROC	O
analysis	O
demonstrated	O
that	O
the	O
ROC	O
area	O
of	O
the	O
Hangzhou	O
criteria	I:C0679228
&	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
method	O
was	O
0.768	O
for	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
.	O

Multivariate	O
analysis	O
confirmed	O
that	O
platelet	B:C0022885
-	I:C0022885
to	I:C0022885
-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
was	O
independently	O
associated	O
with	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Multivariate	O
analysis	O
confirmed	O
that	O
platelet	O
-	I:C0022885
to	I:C0022885
-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
was	O
independently	O
associated	O
with	O
recurrence	B:C2919551
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Multivariate	O
analysis	O
confirmed	O
that	O
platelet	O
-	I:C0022885
to	I:C0022885
-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
was	O
independently	O
associated	O
with	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	B:C0679228
but	O
fulfilling	O
the	O
Hangzhou	O
criteria	I:C0679228
.	O

Multivariate	O
analysis	O
confirmed	O
that	O
platelet	O
-	I:C0022885
to	I:C0022885
-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
≥	O
120	O
was	O
independently	O
associated	O
with	O
recurrence	O
-	I:C2919551
free	I:C2919551
survival	I:C2919551
of	O
patients	O
exceeding	O
the	O
Milan	O
but	O
fulfilling	O
the	O
Hangzhou	B:C0679228
criteria	I:C0679228
.	O

The	O
Hangzhou	B:C0679228
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	B:C3841811
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	B:C0022885
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	B:C0521158
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	B:C1709854
;	O
this	O
approach	O
expands	O
the	O
Milan	O
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

The	O
Hangzhou	O
criteria	I:C0679228
combined	O
with	O
the	O
pre-transplant	O
platelet	O
-	I:C0022885
to-	I:C0022885
lymphocyte	I:C0022885
ratio	I:C0022885
can	O
accurately	O
exclude	O
high	O
-	I:C0332167
risk	I:C0332167
tumor	O
recurrence	I:C0521158
recipients	O
;	O
this	O
approach	O
expands	O
the	O
Milan	B:C0679228
criteria	I:C0679228
effectively	O
without	O
any	O
sacrifice	O
.	O

